AstraZeneca's Tagrisso (osimertinib) — a third-generation EGFR inhibitor — uses a clever aminopyrimidine core. Our process chemistry team scaled this complex molecule to metric-ton production.
3:07:40 AM · Jul 19, 2026
1
Sign in to reply and join the conversation.